Login to Your Account



FDA Clears Amylin's Symlin; Exenatide Still Awaiting Word

By Randall Osborne


Friday, March 18, 2005
It's one down, one to go for Amylin Pharmaceuticals Inc., which won a hard-fought approval by the FDA of injectable Symlin (pramlintide acetate) for patients with Type I or Type II diabetes, whose insulin is not giving them glucose control. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription